Le Lézard
Classified in: Health
Subject: MRR

North America and Europe Managed Equipment Services (MES) Markets Report 2024-2028: New Business Models and Digital Capabilities Drive Uptake to Address Cost Challenges and Outdated Technology

DUBLIN, Feb. 23, 2024 /PRNewswire/ -- The "North America and Europe Managed Equipment Services (MES) Market, Forecast to 2028" report has been added to  ResearchAndMarkets.com's offering.

Research and Markets Logo

The study period is 2022-2028, with 2023 as the base year and 2024-2028 as the forecast period. The study overviews the North American and European MES markets, focusing on current scenarios, drivers and restraints, the latest technologies, and notable participants.

As the number of aging, technologically obsolete imaging systems at medical facilities increases the need to shift to new imaging equipment with advanced technology, hospitals and imaging centers - especially in developing economies - seek MES models that provide a viable long-term equipment procurement strategy. MES offers technical infrastructure support to a healthcare organization for a service fee through a long-term contract, often over 8 years. Based on technology usage, the service fee includes fixed and variable components such as per patient, test, or diagnosis.

The publisher expects MES to sustain steady growth during the next 5 years, fueled by healthcare organizations' need to optimize the total cost of ownership and adopt business models that will help hospitals and imaging facilities shift from capital to operating expenditure. We anticipate the rapid adoption of MES as a business model across radiology practices, especially among mid and small-sized radiology centers.

The research team aims to offer stakeholders insights into the MES market to enable them to monetize opportunities arising from this advanced yet dynamic landscape over the next few years.

Growth Opportunity Universe

The report segments the MES market into the following categories:

Key Topics Covered:

Strategic Imperatives

Growth Opportunity Analysis

North America


For more information about this report visit https://www.researchandmarkets.com/r/asei4q

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

These press releases may also interest you

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

News published on and distributed by: